Results of Transrectal Ultrasound-Guided Biopsies and Clinical Significance of Japanese Prostate Cancer

Japanese Journal of Clinical Oncology

Volumn 28, Issue 11, 1998, Pages 666-672

  Egawa, Shin ^a   Matsumoto, Kazumasa ^a   Yoshida, Kazunari ^a   Iwamura, Masatsugu ^a   Kuwao, Sadahito ^a   Koshiba, Ken ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical significance; Prostate cancer; Repeat biopsy; Transrectal ultrasound guided biopsy; Tumor volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOPSY; BLOOD; ECHOGRAPHY; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0032214867     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.11.666     Document Type: Article

References (26)

1. Kakizoe T. Figures on Cancer in Japan-1995. Foundation for Promotion of Cancer Research, Tokyo, 1995;34-5 (in Japanese).
2. Tominaga S, Aoki K, Hanai A, Kurihara N. Cancer Statistics - Incidence/ Mortality/Prognosis, 1993 Shinohara Publishing Co., Tokyo, 1993:154-70 (in Japanese).
3. Statistics and Information Department. Vital Statistics 1995 Japan. Minister's Secretariat, Ministry of Health and Welfare, 1995;3:100-1 (in Japanese).
4. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
5. Egawa S, Matsumoto K, Shitara T, Uchida T, Kuwao S, Koshiba K. Zonal biopsy in the detection of prostate cancer in Japanese men. Jpn J Clin Oncol 1997;28:20-6.
6. Egawa S, Matsumoto K, Iwamura M, Uchida T, Kuwao S, Koshiba K. Impact of life expectancy and tumor doubling time on the clinical significance of prostate cancer in Japan. Jpn J Clin Oncol 1997;27:394-400.
7. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996;156:127-32.
8. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-94.
9. Gronberg H, Damber J-E, Jonsson H, Lenner P. Patient age as a prognostic factor in prostate cancer J Urol 1994;152:892-5.
10. D'Amico AV, Propert KJ. Prosrate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 1996;35:273-9.
11. Machida T, Ohishi Y, Wada T, Akimoto S, Shimazaki J, Oda H, et al. Clinical evaluation of a new kit (IMx PA Dainapack) for detection of serum prostate specific antigen. Acta Urol Japonica 1993;39:977-84.
12. Egawa S, Suyama K, Ohori M, Kawakami T, Kuwao S, Hirokado K, et al. Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer 1995;76:463-72.
13. Klee GG, Dodge LA, Zincke H, Oesterling JE. Measurement of serum prostate specific antigen using IMx prostate specific antigen assay. J Urol 1994.151.94-8.
14. Hodge KK, McNeal JE, Stamey TA. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 1989;142:66-70.
15. International Union Against Cancer. TNM Atlas, 3rd edn, 2nd revision. Springer, New York, 1992;241-50.
16. D' Amico AV, Chang H, Holupka E, Renshaw A, Desjarden A, Chen M, et al. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 1997;49:385-91.
17. Imai K, Ichinose Y, Kubota Y, Yamanaka H, Sato J. Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol 1995;154:1085-9.
18. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994;152:1714-20.
19. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stageT1c) prostate cancer. JAMA 1994;271:368-74.
20. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr. editors. Campbell's Urology, 6th edn. Philadelphia, WB Saunders Co., 1992,3.1159-1221
21. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994;152:1732-6.
22. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG. Moul JW. Age-specific reference ranges for serum prostate-specific antigen in black men. New Engl J Med 1996;335:304-10.
23. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.
24. Keetch DW, Catalona WJ, Smith DS. Serial prostate biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-4
25. Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997;158:505-9.
26. Chan LW, Chan PSF, Stamey TA. Calculating prostate cancer volume preoperatively: the D'Amico Equation. J Urol 1998;159A:298.